Journal
PHARMACEUTICALS
Volume 13, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/ph13030038
Keywords
[Ga-68]Ga-DOTA-TOC; positron emission tomography (PET); somatostatin receptor (SSTR); neuroendocrine tumors (NETs); theranostics
Categories
Ask authors/readers for more resources
In the United States, [Ga-68]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first Ga-68-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [Ga-68]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide Ga-68 with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available